Gossamer Bio, Inc. (NASDAQ:GOSS) on Tuesday reported mixed third-quarter financial results.

Gossamer Bio reported quarterly losses of $(7.36) per share which missed the analyst consensus estimate of $(3.68) per share. The company reported quarterly sales of $38.431 million which beat the analyst consensus estimate of $12.148 million.

“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH,” said Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer of Gossamer Bio. “Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”

Gossamer Bio shares fell 4.7% to trade at $10.75 on Wednesday.

These analysts made changes to their price targets on Gossamer Bio following earnings announcement.

• Wedbush analyst Laura Chico maintained the stock with a Neutral and lowered the price target from $80 to $32.
• Piper Sandler analyst Yasmeen Rahimi maintained the stock with an Overweight rating and lowered the price target from $120 to $96.

Considering buying GOSS stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.